<DOC>
	<DOCNO>NCT02568527</DOCNO>
	<brief_summary>The purpose clinical study undertake pilot safety efficacy study synthetic biodegradable membrane substitute use donor human amniotic membrane ( hAM ) treatment limbal stem cell deficiency ( LSCD ) combine freshly excise limbal tissue theatre one stage procedure</brief_summary>
	<brief_title>Biodegradable Synthetic Scaffold Substitute hAM Limbal Epithelial Cells Transplant LSCD Patients</brief_title>
	<detailed_description>This study involve use synthetic biodegradable Poly Lactide-co-Glycolic Acid ( PLGA ) biodegradable , synthetic carrier membrane ( PLGA ) membrane substitute use donor human amniotic membrane ( hAM ) treatment limbal stem cell deficiency ( LSCD ) combine freshly excise limbal tissue theatre one stage procedure . This potential simplify current procedure make safer accessible surgeon eventually benefit patient . The use PLGA membrane , place hAM limbal transplant , novel technique lot promise potential , potentially benefit patient large significantly bring cost limbal transplant reduce disease transmission risk use human donor tissue .</detailed_description>
	<criteria>1 . Male female participant â‰¥18 year age . 2 . Patients confirm diagnosis total LSCD confirm one following : Ingrowth conjunctival epithelium cornea ( conjunctivalization ) , 360o absence limbal Palisades Vogt , A fine stipple appearance fluorescein staining , Persistent recurrent corneal epithelial defect Superficial vascularization , Dull irregular corneal epithelium . 3 . Participants unilateral limbal stem cell deficiency due chemical injury 4 . No prior history limbal transplantation 5 . No ongoing active ocular pathology 6 . No severe pathological psychological condition might interfere patient participation study 7 . Able provide write informed consent prior study specific screen procedure understand patient right withdraw study time , reason without prejudice . 1 . Bilateral LSCD 2 . LSCD due autoimmune disorder partial LSCD 3 . Having ongoing ocular pathology acute ocular inflammation 4 . Previous neoplastic/cancer disease 5 . Severe dry eye confirm Schirmer 's test 6 . Acute systemic infection 7 . Prior history limbal transplantation surgery multiple surgery limbal region 8 . Substance abuse , medical , psychological social condition may , opinion investigator , interfere patient 's participation study evaluation study result . 9 . Any uncontrolled , intercurrent illness opinion Investigator may interfere study evaluation . 10 . Participants uncontrolled diabetes exclude study 11 . History evidence cardiac disease : congestive heart failure ; New York Heart Association ( NYHA ) class 2 great ( see Appendix 6 ) ; active coronary artery disease ; unstable angina , cardiac arrhythmia require antiarrhythmic therapy , atrioventricular block second third degree , uncontrolled hypertension , patient recent ( less 6 month ) myocardial infarction ( MI ) coronary revascularization . 12 . Pregnant lactating patient , positive urine pregnancy test woman childbearing potential 13 . Reproductive age patient practice effective adequate birth control measure 14 . Participation investigational trial receipt investigational drug device occur within 30 day prior screen study . 15 . Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>LSCD</keyword>
	<keyword>SLET</keyword>
	<keyword>Donor Human Amniotic Membrane ( hAM )</keyword>
	<keyword>PLGA</keyword>
</DOC>